TransCode Therapeutics Inc
RNAZ | $0.5 -0.99% -1.0% 280K
|
Professional, Scientific, and T...
(0.0% 1d) (-25.3% 1m) (-93.7% 1y) (0.0% 2d) (-5.8% 3d) (-21.0% 7d) (-88.12% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 2,904,027
https://www.transcodetherapeutics.com
Sec Filling | Patents | 2021 employees
TransCode Therapeutics is an emerging RNA oncology company created to realize its belief that cancer can be defeated through the intelligent design of RNA therapeutics. This belief is based on a new approach to address what TransCode believes has been the most intractable challenge in RNA therapeutics: delivering an oligonucleotide to its target before the body’s immune system can attack and dismantle it. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. TransCode’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which TransCode believes has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. TransCode anticipates submitting an IND, in the second half of 2021 to support initiation of a Phase 0 clinical study with TTX-MC138.
cancer pancreatic glioblastoma
add to watch list Paper trade email alert is off
Press-releases
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.5 -0.99% -1.0% 280K
|
Professional, Scientific, and T...
|
| O: 0.11%
H: 5.95%
C: -13.78%
mc138 fda ttx-mc138 tumors clearance trial therapeutics advanced
TransCode Therapeutics Reports 2023 Results; Provides Business Update
Published: 2024-04-03 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.5 -0.99% -1.0% 280K
|
Professional, Scientific, and T...
|
| O: -1.04%
H: 1.48%
C: -3.7%
business update therapeutics
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
Published: 2024-03-28 (Crawled : 12:30) - globenewswire.com
RNAZ | $0.5 -0.99% -1.0% 280K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.6%
C: 0.6%
medical therapeutics
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
Published: 2024-03-11 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.5 -0.99% -1.0% 280K
|
Professional, Scientific, and T...
|
| O: 2.86%
H: 0.0%
C: -11.14%
report genomics cancer treatment technology therapeutics
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
Published: 2024-03-06 (Crawled : 21:00) - globenewswire.com
RNAZ | $0.5 -0.99% -1.0% 280K
|
Professional, Scientific, and T...
|
| O: 0.57%
H: 3.69%
C: 3.69%
europe congress leaders therapeutics
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
Published: 2024-02-20 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.5 -0.99% -1.0% 280K
|
Professional, Scientific, and T...
|
| O: 1.87%
H: 0.0%
C: -1.84%
patent agonist publication application therapeutics
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
Published: 2024-01-31 (Crawled : 21:00) - globenewswire.com
RNAZ | $0.5 -0.99% -1.0% 280K
|
Professional, Scientific, and T...
|
| O: 4.2%
H: 4.17%
C: -5.26%
nasdaq therapeutics market
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
Published: 2024-01-29 (Crawled : 13:30) - globenewswire.com
RNAZ | $0.5 -0.99% -1.0% 280K
|
Professional, Scientific, and T...
|
| O: 14.42%
H: 1.21%
C: -10.29%
cancer collaboration therapeutics
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
Published: 2024-01-22 (Crawled : 22:00) - globenewswire.com
RNAZ | $0.5 -0.99% -1.0% 280K
|
Professional, Scientific, and T...
|
| O: -2.63%
H: 16.15%
C: -3.96%
million offering therapeutics
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
Published: 2024-01-18 (Crawled : 19:00) - globenewswire.com
RNAZ | $0.5 -0.99% -1.0% 280K
|
Professional, Scientific, and T...
|
| O: -8.44%
H: 1.2%
C: -18.33%
million offering therapeutics
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Last 48 Hours Insiders Buying
IZEA | $2.5 -2.4% 8.6K
|
Technology Services
|
00:00
RKT P 383 | $11.38 -0.52% 1.05% 1.4M
|
Finance
|
22:30
CTRN P 18090 | $22.46 -1.01% -1.02% 55K
|
Retail Trade
|
22:00
BRN P 10650 | $2.795 2.38% 0.18% 35K
|
Energy Minerals
|
21:00
NEOG P 10000 | $12.14 -0.16% -0.16% 3.1M
|
Health Technology
|
16:30
RMCF | $3.51 -3.7% -3.85% 3.8K
|
Consumer Non-Durables
|
20:10